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Mini Abstract / Precis: 
The spinal metastasis invasiveness index (SMII) is comprised of surgical factors, tumor 
vascularity and preoperative embolization, which is able to predict long operative time and 
high blood loss in patients undergoing metastatic spine tumor surgery. SMII can be a tool to 
assist in resource planning, allocation, and patient education. 
 
Abstract 
Study Design: Retrospective review 
Objective: To develop a surgical invasiveness index for metastatic spine tumor surgery 
(MSTS) that can serve as a standardized tool in predicting intraoperative blood loss and 
surgical duration; for the purpose of ascertaining resource requirements and aiding in patient 
education.  
Summary of Background Data: Magnitude of surgery is important in the metastatic spine 
disease (MSD) population since these patients have a continuing postoperative oncological 
process; a consideration that must be taken into account to maintain or improve quality of 
life. Surgical invasiveness indices have been established for general spine surgery, adult 
deformity, and cervical deformity, but not yet for spinal metastasis. 
Methods: Demographic, oncological, and procedural data were collected from consecutive 
patients that underwent MSTS. Binary logistic regression, using median values for surgical 
duration and intraoperative estimated blood loss (EBL), was used to determine statistical 
significance of variables to be included in the “spinal metastasis invasiveness index” (SMII). 
The corresponding weightage of each of these variables was agreed upon by experienced 
spine surgeons. Multi-variable regression analysis was used to predict operative time and 
EBL while controlling for demographical, procedural, and oncological characteristics.  
Results: Two hundred and sixty-one MSD patients were included with a mean age of 59.7-
years and near equal gender distribution. The SMII strongly predicted extended surgical 
duration (R2=0.28,p<0.001) and high intraoperative blood loss(R2=0.18,p<0.001). When 
compared to a previously established surgical invasiveness index, the SMII accounted for 
more variability in the outcomes. For every unit increase in score, there was a 42 mL increase 
in mean blood loss (p<0.001) and 5-minute increase in mean operative time (p<0.001). 
Conclusions: Long surgical duration and high blood loss were strongly predicted by the 
newly developed SMII. The use of the SMII may aid in preoperative risk assessment with the 
goal of improving patient outcomes and quality of life. 
 
Keywords: Blood loss; Operative time; Invasiveness index; Spine metastasis; Surgical 
invasiveness; Tumor surgery; Spine tumor 
Level of Evidence: 4 
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INTRODUCTION 
The spine is the leading site of skeletal metastases that originate from a wide range of 
primary tumors that include lung, breast, prostate, kidney, and thyroid. 1,2 A vast spectrum of 
spinal involvement and radiologic patterns can lead to severe neurological compromise, 
debilitating pain, and spinal instability. Metastatic spine tumor surgery (MSTS) presents a 
challenge to the treating surgeon as preoperative planning must consider health status, 
prognosis, prior radiotherapy (RT) and/or chemotherapy, primary tumor type, extent of 
disease, and spinal alignment. 3-5 The goals of MSTS pivot around adequate decompression 
of neural elements and conferring vertebral column stability; the different techniques and 
approaches to achieve these contribute to variable clinical outcomes and complications. 4 
MSTS differs from other spinal surgeries as patients have a continuing postoperative 
oncological process; a consideration that must be taken into account to maintain quality of 
life. Complications such as extended length of hospital stay, unplanned readmissions, and 
unique adverse events such as recurrence of neurologic deficit from rapid tumor regrowth and 
construct failure in pathologic bone, differ greatly from those found in degenerative spine 
conditions. 2,6-8  
The variability in surgical treatment of similar metastatic spinal disease (MSD) cases 
across different institutions can be attributed to a lack of universal treatment algorithms. An 
objective index would be useful to predict important outcomes in MSTS such as blood loss, 
operative time, postoperative complications, and length of hospital stay to help patients make 
informed decisions about their proposed surgeries. Additionally, such an index would allow 
comparison between surgical outcomes within and between different spine centers treating 
MSD. Mirza et al 9 was the first to develop such an index for spine surgeries wherein a point 
value was assigned to each component of the procedure. The sum of the components became 
the total surgical invasiveness score which was validated to assess surgical duration and 
intraoperative blood loss. Similar indices have been developed for both adult spinal deformity 
and cervical deformity procedures. 10,11 However, these scoring systems are biased towards 
predicting invasiveness for degenerative spinal deformities and are inappropriate for MSTS.  
No studies to date have developed an invasiveness index specific to the metastatic 
spine population. Therefore, we aimed to develop a surgical invasiveness index for spinal 
metastasis with internal validation by evaluating its association with blood loss and operative 
time. We selected these outcome measures as they have been closely linked with the 
magnitude of surgery and can be quantified objectively. 9-12  
METHODS 
We conducted a retrospective review of MSTS patients in our institution between 
2005 and 2015. Institutional Review Board approval was obtained before study 
commencement. We included all metastatic spine patients that underwent surgical procedures 
and had follow-up data up to 1 year or until their demise. Inclusion criteria were patients > 18 
years with radiological and histological evidence of MSD. Patients with isolated 
vertebroplasty, active/healed spinal infections or exposure to high energy trauma preceding 
surgery were excluded.  
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Demographic and clinical data collected included patient age, sex, BMI, Charlson 
Comorbidity Index (CCI), and European Cooperative Oncology Group Performance 
(ECOG). Oncologic data acquired included primary tumor type, extent of metastases (i.e. 
visceral and vertebral), levels of cord compression, preoperative and/or postoperative RT and 
preoperative embolization. Surgical data collected included operative time, estimated blood 
loss (EBL), surgical approach, levels of instrumentation, and levels of decompression. 
Development of the Spinal Metastasis Invasiveness Index 
The components considered for inclusion in the index were derived from the 
previously published study by Mirza et al. 9 We decided to use operative time and EBL as 
direct measures of surgical invasiveness and forewent length of hospital stay, adverse events, 
and unplanned readmission as these could be due to the sequelae of patients’ oncological 
disease process and not surgical invasiveness itself. Patient and operative variables predicting 
high operative time and EBL based on their medians (operative time >230 minutes, EBL 
>650 mL) were evaluated using binary logistic regression. Variables that were significant in 
the binary logistic regression were considered for the development of the index. Experienced 
spine surgeons were consulted and reached a consensus on the selected weightage for each 
variable to create the “spinal metastasis invasiveness index” (SMII). Multivariable regression 
analysis was used to predict operative time and EBL while controlling for demographical, 
procedural, and oncological characteristics. SPSS version 23 (Armonk, NY) was used for all 
statistical analyses and significance level was set at 0.05. 
RESULTS 
A total of 261 MSTS patients with complete baseline demographic, clinical, surgical 
details and follow-up data were included. Mean age was 59.7 + 11.5 years and 50.6% of the 
cohort were female (Table 1).  Patients had a median CCI of 7 and average preoperative 
ECOG score of 1.3 + 1.0. The cohort had an average of 6.2 + 2.9 levels instrumented and 1.8 
+ 1.3 levels decompressed, with 12.3% anterior-only surgeries, 76.6% posterior-only, and 
11.1% combined.  Average EBL was 824.5 + 685.4 mL, and average operative time was 
253.4 + 113.3 minutes. Majority of tumors were from a lung primary (30.3%), followed by 
breast (18.6%) and prostate (8.9%) (Table 2). 
Spinal Metastasis Invasiveness Index 
The variables included in the newly developed SMII (Table 3) with their 
corresponding weightage were: total corpectomy from any approach (4 per level), 
hemicorpectomy from any approach (3 per level), pediculectomy (2 per pedicle), posterior 
decompression (2 per level), anterior column support i.e. cement spacer, graft and cage (2 per 
level attached to and replacing vertebral bodies), open posterior instrumentation (2 per level), 
posterior percutaneous surgical fixation (PPSF) (1 per level), and vertebroplasty (1 per level). 
These variables were carefully chosen to reduce any interobserver ambiguity as each 
operative procedure can be dissected into these above mentioned operative components.  
The SMII is a tool primarily developed to predict blood loss and operative time. Of all 
the preoperative variables, tumor vascularity and embolization would have the largest 
influence on blood loss. 13,14 Hence, we decided to include only the above 2 factors as 
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modifiers. Hypervascular tumors (i.e. renal, thyroid, hepatocellular, etc.) were awarded a 
modifier of 2 per level decompressed, separately scored for anterior and posterior column. 
Similarly, for absence of preoperative embolization, we awarded a modifier of 1 per level, 
separately scored for anterior and posterior column.   
The newly developed SMII predicted high intraoperative blood loss (R2=0.18, 
p<0.001), and extended operative time (R2=0.28, p<0.001). When compared to the Mirza et 
al 9 index (Table 4), the SMII accounted for more variability in both outcomes. The SMII 
explained 18% of the variation in EBL as against 13% by Mirza et al.’s 9 index; similarly, 
SMII explained 28% of the variation in operative time as against 14%. For every 1-point 
increase in the SMII score, there was a 42 mL increase in mean blood loss (p <0.001) and 5-
minute increase in mean operative time (p<0.001). 
Case Examples 
Figure-1 presents preoperative and postoperative radiographs for a patient who 
underwent an uncomplicated PPSF from T11 to L3. The spinal instability neoplastic score 
(SINS) of the patient was 12 and the modified Tokuhashi score was 13. The scores based on 
the surgical invasiveness index of Mirza et al 9 and newly developed SMII were both 4. The 
EBL was 50 mL and operative time was 146 minutes.  
Figure-2 presents preoperative and postoperative radiographs for a patient who 
underwent an uncomplicated anterior L2 corpectomy with cage support and PPSF from T12 
to L4. The SINS of the patient was 14 and the modified Tokuhashi score was 11. The patient 
had renal cell carcinoma but had preoperative embolization. The score based on the Mirza et 
al 9 index was 10 while the score using the newly developed SMII was 16 (i.e. 4 points for 
one level corpectomy, 2 points for the hypervascular tumor modifier, 6 points for use of 
anterior expandable cage, 4 points for 4 levels of MIS posterior instrumentation). The EBL 
was 610 mL and operative time was 226 minutes.  
Figure-3 presents preoperative and postoperative radiographs for a patient who 
underwent an open posterior instrumentation from T2 to T11 and subsequent anterior T6 to 
T8 corpectomies with reconstruction. The SINS of the patient was 12 and the modified 
Tokuhashi score was 8. This patient suffered from lung adenocarcinoma and was not 
embolized preoperatively. The invasiveness score according to Mirza et al 9 was 16 while our 
score using the SMII was 39 (i.e. 14 points for open posterior instrumentation, 12 points for 3 
corpectomies plus 3 points for no embolization, 10 points for anterior support). The EBL was 
2700 mL and operative time was 396 minutes. 
DISCUSSION 
The SMII was envisaged to predict EBL and operative time for MSTS, better than a 
previously established invasiveness index for general spine surgery. Intraoperative blood loss 
and surgical duration have been shown by numerous studies 9-12 to be associated with 
extensive spinal surgeries and are logical, quantifiable markers of surgical invasiveness.  By 
refining the components of the surgical invasiveness index of Mirza et al, 9 we have 
developed a novel SMII specifically tailored to patients with MSD that was able to 
successfully predict the magnitude of surgery. 
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Recently, a novel cervical deformity surgical invasiveness index utilized length of 
stay as another outcome measure. 11 We acknowledge that this is applicable to MSTS patients 
as extended hospital stay reflects longer recovery from complex spinal procedures and 
accounts for occurrence of postoperative complications. 6,15 Similarly, Zaw et al. 16 
highlighted that operative parameters such as EBL and length of surgery may considerably 
influence the risk of postoperative complications after MSTS. Therefore, SMII may be 
considered as an indirect predictor of the risk of postoperative complications such as urinary 
tract infections, pneumonia, or deep vein thrombosis. Nonetheless, MSTS patients are a 
unique population whose primary oncological process continues even after successful and 
uneventful spinal surgery. Numerous sequelae from other organ systems affected by their 
cancer can manifest postoperatively and affect length of hospital stay and the risk of 
postoperative medical complications. 17 Hence, directly associating our index with the length 
of hospital stay or the risk of postoperative complications may obscure the true effect of 
surgery on these parameters. This same principle applies to other measures of surgical 
outcome in MSTS such as unplanned hospital readmissions.  
We understand that multiple factors can influence operative time and intraoperative 
blood loss in MSTS. Renal, thyroid, hepatic and other primary cancers tend to produce 
hypervascular metastatic lesions that bleed profusely, leading to increased intraoperative 
blood loss and operative times. 14 Conversely, preoperative embolization is known to reduce 
blood loss and hasten decompression. 13 Hence, we decided to include these variables to 
calculate the index as it makes the SMII more comprehensive. 
Other indices such as those of Neuman et al. 10 and Passias et al. 11 dealing with adult 
spinal deformity and cervical deformity, respectively, are justified in their use of radiographic 
measurements. Larger and more extensive deformity corrections are reasonably associated 
with a higher degree of invasiveness and surgical complexity. 18 However, MSTS patients 
usually present with neurological deficits or pain that preclude them from obtaining full 
length standing radiographs. In addition, MSTS patients have a low overall mean survival of 
• 10 months 18-20 with decreased physiologic demands or functional status in the postoperative 
period. For these reasons, we deemed it unnecessary to include angular measurements 
pertaining to global and regional sagittal alignment in our invasiveness index.  
Variables such as age, CCI, ECOG and neurological status, were also not included in 
the scoring system as these variables did not significantly predict both increased EBL and 
prolonged surgical duration in binary logistic regression analysis. Mirza et al. 9 highlighted 
that although age, comorbidities and neurological status influence blood loss and duration of 
surgery, they account for only about 1%–5% of the variation. Furthermore, inclusion of these 
variables would render the SMII too complex, thereby, limiting its utilization. As a whole, 
one of our primary objectives was to produce a system where scores would be simple to 
calculate as in the scoring system by Mirza et al., 9 but still account for more variability in 
operative time and blood loss in MSTS. However, we believe that the SMII can be used in 
conjunction with other established scoring systems that include patient factors and address 
health related quality of life, to better tailor the surgical procedure to the patient.  
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
There are no other studies that have attempted to apply a surgical invasiveness index 
to patients with MSD. MSTS has different aims of care than patients undergoing surgery for 
degenerative spinal conditions; wherein the most important being the maintenance or 
improvement of quality of life. In addition, it alleviates spinal symptoms and provides local 
control of the tumor. Ultimately, surgery in MSD will never achieve total cure of the primary 
cancer, hence meticulous planning is needed to assure the best possible outcomes.  Metastatic 
spinal decompression and reconstruction are, for the most part, challenging and technically 
difficult, hence factors to assess surgical invasiveness are likely to be different than those 
used for the general spine population.  
The study of Mirza et al 9 included a case mix of spinal conditions in their cohort 
which included degenerative, trauma, tumors, infections and revisions. Tumors accounted for 
only 7.4% of the entire cohort and it was unclear whether they were metastatic or primary in 
nature. The development of SMII specific to MSD is important to aid in preoperative 
planning and risk assessment of this fragile population. Patients undergoing MSTS have 
poorer health status than those with degenerative conditions as highlighted by the higher 
scores (CCI mean: 7.3 + 1.4) compared to that of studies investigating deformity invasiveness 
indices (CCI mean: 2 + 2). 9,10 MSTS patients can present with multiple symptomatic 
vertebrae at different regions along the spinal column, which can cause difficulty in 
prioritizing and staging of surgery. Intraoperatively, decompression of pathologic vertebral 
elements carries a higher risk of increased blood loss that can indirectly lead to a longer 
procedure. Fusion in MSTS constructs is also seldom performed and only suitable in patients 
with good prognosis and projected long-term survival. We believe there is value in a scoring 
system to predict magnitude of surgery in patients where there is a wide range of preoperative 
considerations. 
Efforts to improve the accuracy of predicting quantifiable outcomes of surgery are 
likely to improve patient safety, quality of life, and efficiency of spinal care. With MSTS 
involving • 4 levels of spinal instrumentation and • 1  level of decompression, there is 
considerable risk of complications. MSTS is associated with a 29% risk of complications, 21 
but the reports range from 10 to 66.7% in existing literature. 22 The utility of an invasiveness 
index would allow surgeons to adequately prepare for their interventions based on the 
patient’s preoperative status. High scores can signal providers to consider appropriate 
resource planning for extensive surgery, optimizing general condition of the patient, and 
performing neoadjuvant treatments. Conversely, lower scores would favor early surgery to 
address potential vertebral instability or to separate neural elements from pathologic tissue for 
subsequent radiation therapy (i.e. separation surgery). 23,24 In addition, this index would assist 
in proper resource management and allocation in terms of anesthetic support, blood product 
management, and pre-booking of intensive care units. 16,25 
Limitations 
The retrospective review of patient data for this study could potentially introduce 
selection and information bias. A prospective study may be needed to further validate our 
study findings. We relied on the data of patients that spanned over a period of 10 years where 
surgical techniques have evolved especially in the field of MSD. Despite the limitations 
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stated above, our cohort only contained patients who underwent MSTS which was different 
from the study by Mirza et al. 9 which included patients from the full spectrum of spinal 
surgery. This might theoretically limit the comparisons made between the two indices. This 
does, however, highlight the need for a separate invasiveness index specific for MSTS. The 
SMII developed in this study only explains trends in EBL and operative time but cannot 
predict the actual numeric values of these outcomes. This could be attributed to other factors 
in MSTS that could potentially contribute to its invasiveness. 
CONCLUSION 
Ours is the first study to date to develop a novel “surgical invasiveness index” specific 
to the metastatic spine tumor population. Surgical duration and blood loss were strongly 
predicted by the newly developed “spinal metastasis invasiveness index” (SMII), 
incorporating surgical factors clinically relevant for patients undergoing MSTS. The SMII 
accounted for more variability than the previously established invasiveness index. This index 
will allow surgeons to gauge the intraoperative blood loss and surgical duration of their 
proposed procedures, aiding in resource management. Additionally, this will indirectly 
improve risk assessment of patients undergoing MSTS.  
 
Key Points 
1. An invasiveness index for spinal metastasis is important to assess magnitude of 
surgery which may have repercussions on the continuing oncologic process that these 
patients still must contend with postoperatively. 
2. The spinal metastasis invasiveness index (SMII), which is comprised of surgical 
factors, tumor vascularity, and embolization status, strongly predicted increased 
operative time and intraoperative blood loss. 
3. This index can assist in proper resource management and allocation in terms of 
anesthetic support, blood product management, and pre-booking of intensive care 
facilities for this already fragile population. 
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Figure 1: Preoperative and postoperative images of a patient who underwent minimally 
invasive T11 to L3 posterior instrumentation for symptomatic and potentially unstable L1 
metastasis of the cervix. 
 
 
 
Figure 2: Preoperative and postoperative images of a patient who underwent minimally 
invasive T12 to L4 posterior instrumentation with anterior reconstruction for an L2 
pathologic fracture secondary to metastatic renal cell carcinoma. 
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Figure 3: Preoperative and postoperative images of a patient who underwent open T2 to T11 
posterior instrumentation and T6 to T8 corpectomies with anterior support for metastatic 
lung adenocarcinoma. 
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Tables 
Table 1. Baseline Demographic, Clinical, and Surgical Details for MSTS Patients. 
Demographic Variables Mean + standard deviation or N (%) 
Age, years 59.7 + 11.5  
Gender, female 132 (50.6%) 
BMI, kg/m2 23.2 + 4.8 
CCI 7.3 + 1.4 
ECOG 1.3 + 1.0 
Surgical Variables  
Surgical approach  
Anterior 32 (12.3%) 
Posterior 200 (76.6%) 
Combined 29 (11.1%) 
Levels decompressed 1.8 + 1.3 
0 38(14.6%) 
1-2 155 (59.4%) 
3-4 58 (22.2%) 
>4 10 (3.8%) 
Levels instrumented 6.2 + 2.9 
<6 127 (48.7%) 
6-9 102 (39.1%) 
>9 32 (12.2%) 
Preoperative Embolization 58 (22.2%) 
Outcomes  
Estimated blood loss, mL 824.5 + 685.4 
Operative time, min 253.4 + 113.3 
CCI - Charlson Comorbidity Index; ECOG - European Cooperative Oncology Group 
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Table 2. Baseline Oncologic Overview of 261 MSTS Patients. 
Primary Tumor N (%) 
Lung 82 (31.4%) 
Breast 45 (17.2%) 
Prostate 25 (9.6%) 
Thyroid 7 (2.7%) 
Renal 20 (7.7%) 
Gastrointestinal 20 (7.7%) 
Nasopharyngeal 9 (3.4%) 
Liver, Gallbladder 12 (4.6%) 
Marrow 22 (8.4%) 
Genitourinary tract 16 (6.1%) 
Others 3 (1.1%) 
Metastatic Profile N (%) 
Pathologic Fracture  161 (61.7%) 
Previous RT 97 (49.3%) 
Visceral Metastasis 79 (30.3%) 
Vertebral Metastasis, levels  
1 60 (23.0%) 
2 67 (25.7%) 
• 3 134 (51.3%) 
Cord Compression, levels  
0 10 (3.8%) 
1 28 (10.7%) 
2 86 (33.0%) 
3 137 (52.5%) 
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Table 3. Components Used to Calculate the Spinal Metastasis Invasiveness Index (SMII). 
Factors Points Assigned 
Total Corpectomya 4 points per level 
Hemicorpectomya 3 points per level 
Anterior column support (cement spacer / 
graft / cage) 
2 points per level spanned in order to replace 
the vertebral body/bodies 
 
Pediculectomy 2 points per pedicle 
Posterior decompression 2 point per level 
Posterior instrumentation 
Open 
Minimally invasive 
 
2 points per level 
1 point per level 
Vertebroplasty 1 point per level 
Modifiers: 
Hypervascular primary tumor (i.e. thyroid, 
renal, liver, gallbladder) 
 
No preoperative embolization 
 
 
2 points per level decompressed a, b 
1 point per level decompressed a, b 
a Regardless of type of approach, b Count separate for anterior and posterior decompression 
 
 
Table 4: Correlations of Surgical Invasiveness Indices with Estimated Blood Loss and 
Operative Time 
 
Index 
Estimated blood loss Operative Time 
Pearson 
correlation 
coefficient (r) 
% of variability 
explained (R2) 
Pearson 
correlation 
coefficient (r) 
% of variability 
explained (R2) 
Mirza et al 0.36 0.13 0.38 0.14 
SMII 0.42 0.18 0.53 0.28 
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